A Study of the Natural Progression of Interstitial Lung Disease (ILD)
University of Chicago · with Idiopathic Pulmonary Fibrosis Clinical Research Network, National Institute of Allergy and Infectious Diseases (NIAID) · NCT00470327
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 4000
- US sites recruiting
- 1
- Study start
- September 2005
- Record last updated
- June 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Conditions: Interstitial Lung Diseases; Idiopathic Pulmonary Fibrosis; Sarcoidosis; Connective Tissue Disorder
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Interstitial lung disease
Exclusion Criteria
- Does not have Interstitial lung disease
Recruiting US locations
University of Chicago
Chicago, IL 60637
Site contact: Mary E Strek, MD · 773-702-3609 · mstrek@medicine.bsd.uchicago.edu
Study contacts (from the official record)
- Vanita Patel, MPH · 773-702-1012
Similar studies in Illinois
All healthy volunteers studies in Illinois →- RecruitingHealthy volunteers
J-RISE: Relevant Implementation Strategies to Eliminate the Social and Structural Barriers to HIV Services Among Justice-involved Black Men Who Have Sex With Men and Other Key Populations
University of Chicago
- Location
- Chicago, IL
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Melrose Park, IL + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
AbbVie
- Location
- Grayslake, IL + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers
AbbVie
- Location
- Grayslake, IL
- Eligibility basics
- Ages 18–65